米氮平联合无抽搐电休克治疗难治性抑郁症对照研究

目的：探讨米氮平联合无抽搐电休克治疗难治性抑郁症的临床疗效和安全性。方法将74例难治性抑郁症患者随机分为研究组38例，对照组36例，两组均口服米氮平治疗，研究组在此基础上联合无抽搐电休克治疗，观察8周。于治疗前后采用汉密顿焦虑量表、汉密顿抑郁量表、临床疗效总评量表评定临床疗效，副反应量表评定不良反应。结果治疗8周末研究组有效率为78．9％，对照组为52．8％，研究组显著高于对照组（χ2＝5．66，P＜0．05）；两组不良反应均较轻微，发生率比较差异无显著性（P＞0．05）。结论米氮平联合无抽搐电休克治疗难治性抑郁症起效快，疗效显著，安全性高，优于单用米氮平治疗。

A control study of mirtazapine plus MECT in treatment-resist-ant depression

Objective To explore the efficacy and safety of mirtazapine plus modified electroconvulsive therapy （MECT） in treatment-resistant depression （TRD） .Methods Seventy-four TRD patients were randomly assigned to research （n=38） and control group （n=36） ,both groups took orally mirtazapine , research group was plus MECT for 8 weeks .Efficacies were assessed with the Hamilton Anxiety Scale （HAMA） ,Hamilton Depression Scale （HAMD） and Clinical Global Impression （CGI） before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale （TESS） .Results At the end of the 8th week effective rate was respectively 78 .9% in research and 52 .8% in control group ,the for-mer was significantly higher than the latter （χ2 =5 .66 ,P〈0 .05）;adverse reactions of both groups were mild and their incidences had no significant group differences （P〉 0 .05） .Conclusion Mirtazapine plus MECT takes effect more rapidly and has an evident effect and higher safety compared with mirtazapine a-lone in treatment-resistant depression .